Chime Biologics Announced Global Strategic Cooperation with Panolos Bioscience to Advance Multi-specific Therapeutic Proteins Development
This article is featured on another website.
Actym Closes $59.5 Million Series A with New $25.5 Million Extension
Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, CA — October 18, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today […]
Actym Closes $59.5 Million Series A with New $25.5 Million Extension
Actym Therapeutics adds $25.5 million to close its Series A with $59.5 million total New investor GKCC LLC joins syndicate Capital will propel lead program ACTM-838 into first-in-human oncology trial and further advance proprietary STACT platform BERKELEY, CA — October 18, 2023 Actym Therapeutics, pioneering a new drug modality to treat solid tumors, announced today […]
Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…
Myrtelle Announces Presentation at the 5 th Annual Gene Therapy for Neurological Disorders Summit: Optimizing Gene Therapies Targeting the CNS to Deliver Safe & Efficacious Treatment Options For Neurological Disorder Patients
Wakefield, Mass., November 7, 2023 – Myrtelle Inc. (“Myrtelle” or the “Company”), a clinical-stage gene therapy company focused on developing transformative treatments for neurodegenerative diseases…